Interim Results from the Phase 3 Hgb-207 (Northstar-2) and Hgb-212 (Northstar-3) Studies of Betibeglogene Autotemcel Gene Therapy (LentiGlobin) for the Treatment of Transfusion-Dependent ß-Thalassemia.

Jennifer Schneiderman, Alexis A. Thompson, Mark C. Walters, Janet L. Kwiatkowski, Andreas E. Kulozik, Martin G. Sauer, John B. Porter, Isabelle Thuret, Suradej Hongeng, Ashutosh Lal, Adrian J. Thrasher, Evangelia Yannaki, Heidi Elliot, Ge Tao, Weijian Liu, Richard A. Colvin, Franco Locatelli